Tislelizumab (BGB-A317)
Jump to navigation
Jump to search
Note: Tislelizumab is approved in China for multiple indications, but does not appear to have a brand name at this time.
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Bladder cancer
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
Also known as
- Code name: BGB-A317
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Bladder cancer medications
- Esophageal cancer medications
- Hepatocellular carcinoma medications
- Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- NMPA approved drugs